{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T09:02:39Z","timestamp":1789549359083,"version":"build-2803163510"},"reference-count":77,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T00:00:00Z","timestamp":1787529600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Rheumatol"],"published-print":{"date-parts":[[2026,10]]},"DOI":"10.1007\/s10067-026-08368-5","type":"journal-article","created":{"date-parts":[[2026,8,24]],"date-time":"2026-08-24T13:21:59Z","timestamp":1787577719000},"page":"5963-5978","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":0,"title":["Mechanism-informed combination therapy and dynamic risk stratification in lupus nephritis: toward durable renal protection"],"prefix":"10.1007","volume":"45","author":[{"ORCID":"https:\/\/orcid.org\/0009-0000-9603-7729","authenticated-orcid":false,"given":"Xiaojing","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0003-9766-1656","authenticated-orcid":false,"given":"Zhichun","family":"Liu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,8,24]]},"reference":[{"key":"8368_CR1","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/ard-2023-224762","volume":"83","author":"A Fanouriakis","year":"2023","unstructured":"Fanouriakis A, Kostopoulou M, Andersen J et al (2023) EULAR recommendations for the management of systemic lupus erythematosus: 2023 update. Ann Rheum Dis 83:15\u201329. https:\/\/doi.org\/10.1136\/ard-2023-224762","journal-title":"Ann Rheum Dis"},{"key":"8368_CR2","doi-asserted-by":"publisher","first-page":"713","DOI":"10.1136\/annrheumdis-2020-216924","volume":"79","author":"A Fanouriakis","year":"2019","unstructured":"Fanouriakis A, Kostopoulou M, Cheema K et al (2019) 2019 update of the Joint European League Against Rheumatism and European Renal Association-European Dialysis and Transplant Association (EULAR\/ERA-EDTA) recommendations for the management of lupus nephritis. Ann Rheum Dis 79:713\u2013723. https:\/\/doi.org\/10.1136\/annrheumdis-2020-216924","journal-title":"Ann Rheum Dis"},{"key":"8368_CR3","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1136\/annrheumdis-2021-221270","volume":"81","author":"I Parodis","year":"2022","unstructured":"Parodis I, Houssiau FA (2022) From sequential to combination and personalised therapy in lupus nephritis: moving towards a paradigm shift? Ann Rheum Dis 81:15\u201319. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221270","journal-title":"Ann Rheum Dis"},{"key":"8368_CR4","doi-asserted-by":"publisher","first-page":"1103","DOI":"10.1681\/asn.2008101028","volume":"20","author":"GB Appel","year":"2009","unstructured":"Appel GB, Contreras G, Dooley MA et al (2009) Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20:1103\u20131112. https:\/\/doi.org\/10.1681\/asn.2008101028","journal-title":"J Am Soc Nephrol"},{"key":"8368_CR5","doi-asserted-by":"publisher","first-page":"1471","DOI":"10.1056\/NEJMoa2410965","volume":"392","author":"RA Furie","year":"2025","unstructured":"Furie RA, Rovin BH, Garg JP et al (2025) Efficacy and safety of obinutuzumab in active lupus nephritis. N Engl J Med 392:1471\u20131483. https:\/\/doi.org\/10.1056\/NEJMoa2410965","journal-title":"N Engl J Med"},{"key":"8368_CR6","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1136\/ard-2023-225319","volume":"83","author":"M Kostopoulou","year":"2023","unstructured":"Kostopoulou M, Mukhtyar CB, Bertsias G, Boumpas DT, Fanouriakis A (2023) Management of systemic lupus erythematosus: a systematic literature review informing the 2023 update of the EULAR recommendations. Ann Rheum Dis 83:1489\u20131501. https:\/\/doi.org\/10.1136\/ard-2023-225319","journal-title":"Ann Rheum Dis"},{"key":"8368_CR7","doi-asserted-by":"publisher","first-page":"1115","DOI":"10.1002\/art.43212","volume":"77","author":"LR Sammaritano","year":"2024","unstructured":"Sammaritano LR, Askanase A, Bermas BL et al (2024) 2024 American College of Rheumatology (ACR) guideline for the screening, treatment, and management of lupus nephritis. Arthritis Rheumatol 77:1115\u20131135. https:\/\/doi.org\/10.1002\/art.43212","journal-title":"Arthritis Rheumatol"},{"issue":"105","key":"8368_CR8","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2023.09.002","volume":"2024","author":"KDIGO","year":"2024","unstructured":"KDIGO (2024) clinical practice guideline for the management of LUPUS NEPHRITIS. Kidney Int 2024(105):S1-s69. https:\/\/doi.org\/10.1016\/j.kint.2023.09.002","journal-title":"Kidney Int"},{"key":"8368_CR9","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1016\/j.kint.2021.08.027","volume":"101","author":"BH Rovin","year":"2022","unstructured":"Rovin BH, Furie R, Teng YKO et al (2022) A secondary analysis of the Belimumab International Study in Lupus Nephritis trial examined effects of belimumab on kidney outcomes and preservation of kidney function in patients with lupus nephritis. Kidney Int 101:403\u2013413. https:\/\/doi.org\/10.1016\/j.kint.2021.08.027","journal-title":"Kidney Int"},{"key":"8368_CR10","unstructured":"Administration USFaD (2025) GAZYVA (obinutuzumab) injection: prescribing information. [cited 12 July 2026]; Available from:\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125486s037s038lbl.pdf"},{"key":"8368_CR11","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.ard.2025.09.007","volume":"85","author":"A Fanouriakis","year":"2026","unstructured":"Fanouriakis A, Kostopoulou M, Anders HJ et al (2026) EULAR recommendations for the management of systemic lupus erythematosus with kidney involvement: 2025 update. Ann Rheum Dis 85:75\u201390. https:\/\/doi.org\/10.1016\/j.ard.2025.09.007","journal-title":"Ann Rheum Dis"},{"key":"8368_CR12","doi-asserted-by":"publisher","first-page":"1070","DOI":"10.1136\/annrheumdis-2020-217178","volume":"79","author":"CC Mok","year":"2020","unstructured":"Mok CC, Ho LY, Ying SKY, Leung MC, To CH, Ng WL (2020) Long-term outcome of a randomised controlled trial comparing tacrolimus with mycophenolate mofetil as induction therapy for active lupus nephritis. Ann Rheum Dis 79:1070\u20131076. https:\/\/doi.org\/10.1136\/annrheumdis-2020-217178","journal-title":"Ann Rheum Dis"},{"key":"8368_CR13","doi-asserted-by":"publisher","first-page":"1338","DOI":"10.1093\/ndt\/gfv296","volume":"32","author":"A Malvar","year":"2017","unstructured":"Malvar A, Pirruccio P, Alberton V et al (2017) Histologic versus clinical remission in proliferative lupus nephritis. Nephrol Dial Transplant 32:1338\u20131344. https:\/\/doi.org\/10.1093\/ndt\/gfv296","journal-title":"Nephrol Dial Transplant"},{"key":"8368_CR14","doi-asserted-by":"publisher","first-page":"e172569","DOI":"10.1172\/jci.insight.172569","volume":"9","author":"A Fava","year":"2024","unstructured":"Fava A, Buyon J, Magder L et al (2024) Urine proteomic signatures of histological class, activity, chronicity, and treatment response in lupus nephritis. JCI Insight 9:e172569. https:\/\/doi.org\/10.1172\/jci.insight.172569","journal-title":"JCI Insight"},{"key":"8368_CR15","doi-asserted-by":"publisher","first-page":"931","DOI":"10.1038\/nm.1857","volume":"14","author":"C Faul","year":"2008","unstructured":"Faul C, Donnelly M, Merscher-Gomez S et al (2008) The actin cytoskeleton of kidney podocytes is a direct target of the antiproteinuric effect of cyclosporine A. Nat Med 14:931\u2013938. https:\/\/doi.org\/10.1038\/nm.1857","journal-title":"Nat Med"},{"key":"8368_CR16","doi-asserted-by":"publisher","DOI":"10.14814\/phy2.12679","volume":"4","author":"A Wakamatsu","year":"2016","unstructured":"Wakamatsu A, Fukusumi Y, Hasegawa E et al (2016) Role of calcineurin (CN) in kidney glomerular podocyte: CN inhibitor ameliorated proteinuria by inhibiting the redistribution of CN at the slit diaphragm. Physiol Rep 4:e12679. https:\/\/doi.org\/10.14814\/phy2.12679","journal-title":"Physiol Rep"},{"key":"8368_CR17","doi-asserted-by":"publisher","first-page":"201","DOI":"10.1002\/art.27189","volume":"62","author":"AM Jacobi","year":"2010","unstructured":"Jacobi AM, Huang W, Wang T et al (2010) Effect of long-term belimumab treatment on B cells in systemic lupus erythematosus: extension of a phase II, double-blind, placebo-controlled, dose-ranging study. Arthritis Rheum 62:201\u2013210. https:\/\/doi.org\/10.1002\/art.27189","journal-title":"Arthritis Rheum"},{"key":"8368_CR18","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1506298","volume":"16","author":"T Iwasaki","year":"2025","unstructured":"Iwasaki T, Yoshifuji H, Kitagori K et al (2025) Memory B cells and their transcriptomic profiles associated with belimumab resistance in systemic lupus erythematosus in the maintenance phase. Front Immunol 16:1506298. https:\/\/doi.org\/10.3389\/fimmu.2025.1506298","journal-title":"Front Immunol"},{"key":"8368_CR19","doi-asserted-by":"publisher","first-page":"2220","DOI":"10.1093\/rheumatology\/keae364","volume":"64","author":"SY Bang","year":"2025","unstructured":"Bang SY, Joh CS, Itamiya T et al (2025) Unveiling the dynamics of B lymphocytes in systemic lupus erythematosus patients treated with belimumab through longitudinal single-cell RNA sequencing. Rheumatol (Oxford) 64:2220\u20132226. https:\/\/doi.org\/10.1093\/rheumatology\/keae364","journal-title":"Rheumatol (Oxford)"},{"key":"8368_CR20","doi-asserted-by":"publisher","first-page":"1117","DOI":"10.1056\/NEJMoa2001180","volume":"383","author":"R Furie","year":"2020","unstructured":"Furie R, Rovin BH, Houssiau F et al (2020) Two-year, randomized, controlled trial of belimumab in lupus nephritis. N Engl J Med 383:1117\u20131128. https:\/\/doi.org\/10.1056\/NEJMoa2001180","journal-title":"N Engl J Med"},{"key":"8368_CR21","doi-asserted-by":"publisher","first-page":"826","DOI":"10.1002\/art.41608","volume":"73","author":"AD Marinov","year":"2021","unstructured":"Marinov AD, Wang H, Bastacky SI et al (2021) The type II anti-CD20 antibody obinutuzumab (GA101) is more effective than rituximab at depleting B cells and treating disease in a murine lupus model. Arthritis Rheumatol 73:826\u2013836. https:\/\/doi.org\/10.1002\/art.41608","journal-title":"Arthritis Rheumatol"},{"key":"8368_CR22","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1136\/annrheumdis-2021-220920","volume":"81","author":"RA Furie","year":"2022","unstructured":"Furie RA, Aroca G, Cascino MD et al (2022) B-cell depletion with obinutuzumab for the treatment of proliferative lupus nephritis: a randomised, double-blind, placebo-controlled trial. Ann Rheum Dis 81:100\u2013107. https:\/\/doi.org\/10.1136\/annrheumdis-2021-220920","journal-title":"Ann Rheum Dis"},{"key":"8368_CR23","doi-asserted-by":"publisher","first-page":"1502","DOI":"10.2215\/cjn.01070118","volume":"13","author":"LM Gomez Mendez","year":"2018","unstructured":"Gomez Mendez LM, Cascino MD, Garg J et al (2018) Peripheral blood B cell depletion after rituximab and complete response in lupus nephritis. Clin J Am Soc Nephrol 13:1502\u20131509. https:\/\/doi.org\/10.2215\/cjn.01070118","journal-title":"Clin J Am Soc Nephrol"},{"key":"8368_CR24","doi-asserted-by":"publisher","first-page":"915","DOI":"10.1038\/s41590-019-0386-1","volume":"20","author":"E Der","year":"2019","unstructured":"Der E, Suryawanshi H, Morozov P et al (2019) Tubular cell and keratinocyte single-cell transcriptomics applied to lupus nephritis reveal type I IFN and fibrosis relevant pathways. Nat Immunol 20:915\u2013927. https:\/\/doi.org\/10.1038\/s41590-019-0386-1","journal-title":"Nat Immunol"},{"key":"8368_CR25","doi-asserted-by":"publisher","first-page":"287","DOI":"10.1016\/j.autrev.2017.01.010","volume":"16","author":"S Sciascia","year":"2017","unstructured":"Sciascia S, Radin M, Yazdany J et al (2017) Efficacy of belimumab on renal outcomes in patients with systemic lupus erythematosus: a systematic review. Autoimmun Rev 16:287\u2013293. https:\/\/doi.org\/10.1016\/j.autrev.2017.01.010","journal-title":"Autoimmun Rev"},{"key":"8368_CR26","doi-asserted-by":"publisher","unstructured":"Bechman K, Song K, Abhishek Aet al. The 2025 British Society for Rheumatology guideline for the prescription and monitoring of conventional synthetic disease-modifying anti-rheumatic drugs. Rheumatology (Oxford) 2026;65:https:\/\/doi.org\/10.1093\/rheumatology\/keaf522","DOI":"10.1093\/rheumatology\/keaf522"},{"key":"8368_CR27","unstructured":"Administration USFaD (2025) LUPKYNIS (voclosporin) capsules: prescribing information. [cited 12 July 2026]; Available from:\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/213716s008lbl.pdf"},{"issue":"99","key":"8368_CR28","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1016\/j.kint.2020.11.003","volume":"2021","author":"KDIGO","year":"2021","unstructured":"KDIGO (2021) clinical practice guideline for the management of blood pressure in chronic kidney disease. Kidney Int 2021(99):S1-s87. https:\/\/doi.org\/10.1016\/j.kint.2020.11.003","journal-title":"Kidney Int"},{"key":"8368_CR29","doi-asserted-by":"publisher","first-page":"45","DOI":"10.1016\/j.jaut.2018.03.003","volume":"91","author":"T Kraaij","year":"2018","unstructured":"Kraaij T, Kamerling SWA, de Rooij ENM et al (2018) The NET-effect of combining rituximab with belimumab in severe systemic lupus erythematosus. J Autoimmun 91:45\u201354. https:\/\/doi.org\/10.1016\/j.jaut.2018.03.003","journal-title":"J Autoimmun"},{"key":"8368_CR30","doi-asserted-by":"publisher","first-page":"1474","DOI":"10.1093\/ndt\/gfaa117","volume":"36","author":"T Kraaij","year":"2021","unstructured":"Kraaij T, Arends EJ, van Dam LS et al (2021) Long-term effects of combined B-cell immunomodulation with rituximab and belimumab in severe, refractory systemic lupus erythematosus: 2-year results. Nephrol Dial Transplant 36:1474\u20131483. https:\/\/doi.org\/10.1093\/ndt\/gfaa117","journal-title":"Nephrol Dial Transplant"},{"key":"8368_CR31","doi-asserted-by":"publisher","first-page":"510","DOI":"10.1016\/j.autrev.2019.03.004","volume":"18","author":"A Kronbichler","year":"2019","unstructured":"Kronbichler A, Brezina B, Gauckler P, Quintana LF, Jayne DRW (2019) Refractory lupus nephritis: when, why and how to treat. Autoimmun Rev 18:510\u2013518. https:\/\/doi.org\/10.1016\/j.autrev.2019.03.004","journal-title":"Autoimmun Rev"},{"key":"8368_CR32","doi-asserted-by":"publisher","first-page":"3713","DOI":"10.1038\/s41591-025-03899-x","volume":"31","author":"X Wang","year":"2025","unstructured":"Wang X, Zhang Y, Wang H et al (2025) Allogeneic CD19-targeting T cells for treatment-refractory systemic lupus erythematosus: a phase 1 trial. Nat Med 31:3713\u20133724. https:\/\/doi.org\/10.1038\/s41591-025-03899-x","journal-title":"Nat Med"},{"key":"8368_CR33","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1186\/s13045-026-01779-6","volume":"19","author":"M Hong","year":"2026","unstructured":"Hong M, Wang M, Zeng R et al (2026) BCMA-CD19 armored compound CAR T cells in systemic lupus erythematosus: extended follow-up of a phase 1 clinical trial. J Hematol Oncol 19:13. https:\/\/doi.org\/10.1186\/s13045-026-01779-6","journal-title":"J Hematol Oncol"},{"key":"8368_CR34","doi-asserted-by":"publisher","first-page":"1675","DOI":"10.1016\/j.ard.2025.06.2128","volume":"84","author":"Z Hu","year":"2025","unstructured":"Hu Z, Cai S, Yu Y et al (2025) BCMA-targeted CAR T cell therapy can effectively induce disease remission in refractory lupus nephritis. Ann Rheum Dis 84:1675\u20131683. https:\/\/doi.org\/10.1016\/j.ard.2025.06.2128","journal-title":"Ann Rheum Dis"},{"key":"8368_CR35","doi-asserted-by":"publisher","first-page":"103520","DOI":"10.1016\/j.jaut.2025.103520","volume":"158","author":"D Roccatello","year":"2026","unstructured":"Roccatello D, Barinotti A, Radin M et al (2026) Daratumumab monotherapy reverses the immune and pro-fibrotic profiles in refractory lupus nephritis patients: a pilot case study. J Autoimmun 158:103520. https:\/\/doi.org\/10.1016\/j.jaut.2025.103520","journal-title":"J Autoimmun"},{"key":"8368_CR36","doi-asserted-by":"publisher","first-page":"496","DOI":"10.1136\/annrheumdis-2021-221478","volume":"81","author":"D Jayne","year":"2022","unstructured":"Jayne D, Rovin B, Mysler EF et al (2022) Phase II randomised trial of type I interferon inhibitor anifrolumab in patients with active lupus nephritis. Ann Rheum Dis 81:496\u2013506. https:\/\/doi.org\/10.1136\/annrheumdis-2021-221478","journal-title":"Ann Rheum Dis"},{"key":"8368_CR37","doi-asserted-by":"publisher","DOI":"10.1136\/lupus-2023-000910","volume":"10","author":"D Jayne","year":"2023","unstructured":"Jayne D, Rovin B, Mysler E et al (2023) Anifrolumab in lupus nephritis: results from second-year extension of a randomised phase II trial. Lupus Sci Med 10:e000910","journal-title":"Lupus Sci Med"},{"key":"8368_CR38","unstructured":"ClinicalTrials.gov (2026) Phase 3 study of anifrolumab in adult patients with active proliferative lupus nephritis (IRIS). Available from: https:\/\/clinicaltrials.gov\/study\/NCT05138133. Accessed 12 July 2026"},{"key":"8368_CR39","doi-asserted-by":"publisher","first-page":"100","DOI":"10.1159\/000430458","volume":"1","author":"DY Yap","year":"2015","unstructured":"Yap DY, Chan TM (2015) Lupus nephritis in Asia: clinical features and management. Kidney Dis 1:100\u2013109. https:\/\/doi.org\/10.1159\/000430458","journal-title":"Kidney Dis"},{"key":"8368_CR40","doi-asserted-by":"publisher","first-page":"18","DOI":"10.7326\/m14-1030","volume":"162","author":"Z Liu","year":"2015","unstructured":"Liu Z, Zhang H, Liu Z et al (2015) Multitarget therapy for induction treatment of lupus nephritis: a randomized trial. Ann Intern Med 162:18\u201326. https:\/\/doi.org\/10.7326\/m14-1030","journal-title":"Ann Intern Med"},{"key":"8368_CR41","doi-asserted-by":"publisher","first-page":"613","DOI":"10.3899\/jrheum.2023-0210","volume":"51","author":"T Takeuchi","year":"2024","unstructured":"Takeuchi T, Wakasugi N, Hashida T, Uno S, Makino H (2024) Long-term safety and effectiveness of tacrolimus in patients with lupus nephritis in Japan: 10-year analysis of the real-world TRUST study. J Rheumatol 51:613\u2013621. https:\/\/doi.org\/10.3899\/jrheum.2023-0210","journal-title":"J Rheumatol"},{"key":"8368_CR42","doi-asserted-by":"publisher","first-page":"1468","DOI":"10.1177\/0961203315593166","volume":"24","author":"J Yang","year":"2015","unstructured":"Yang J, Liang D, Zhang H et al (2015) Long-term renal outcomes in a cohort of 1814 Chinese patients with biopsy-proven lupus nephritis. Lupus 24:1468\u20131478. https:\/\/doi.org\/10.1177\/0961203315593166","journal-title":"Lupus"},{"key":"8368_CR43","doi-asserted-by":"publisher","first-page":"157","DOI":"10.2478\/rir-2023-0022","volume":"4","author":"M Petri","year":"2023","unstructured":"Petri M, Fang C, Goldman DW (2023) East-Asian lupus nephritis in the Hopkins lupus cohort. Rheumatol Immunol Res 4:157\u2013161. https:\/\/doi.org\/10.2478\/rir-2023-0022","journal-title":"Rheumatol Immunol Res"},{"key":"8368_CR44","doi-asserted-by":"publisher","first-page":"788","DOI":"10.1016\/j.kint.2018.05.021","volume":"94","author":"M De Rosa","year":"2018","unstructured":"De Rosa M, Azzato F, Toblli JE et al (2018) A prospective observational cohort study highlights kidney biopsy findings of lupus nephritis patients in remission who flare following withdrawal of maintenance therapy. Kidney Int 94:788\u2013794. https:\/\/doi.org\/10.1016\/j.kint.2018.05.021","journal-title":"Kidney Int"},{"key":"8368_CR45","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.kint.2019.07.018","volume":"97","author":"A Malvar","year":"2020","unstructured":"Malvar A, Alberton V, Lococo B et al (2020) Kidney biopsy-based management of maintenance immunosuppression is safe and may ameliorate flare rate in lupus nephritis. Kidney Int 97:156\u2013162. https:\/\/doi.org\/10.1016\/j.kint.2019.07.018","journal-title":"Kidney Int"},{"key":"8368_CR46","doi-asserted-by":"publisher","first-page":"3424","DOI":"10.1093\/rheumatology\/keaa129","volume":"59","author":"I Parodis","year":"2020","unstructured":"Parodis I, Adamichou C, Aydin S et al (2020) Per-protocol repeat kidney biopsy portends relapse and long-term outcome in incident cases of proliferative lupus nephritis. Rheumatology (Oxford) 59:3424\u20133434. https:\/\/doi.org\/10.1093\/rheumatology\/keaa129","journal-title":"Rheumatology (Oxford)"},{"key":"8368_CR47","doi-asserted-by":"publisher","first-page":"1335","DOI":"10.1681\/asn.2019121285","volume":"31","author":"JM Mejia-Vilet","year":"2020","unstructured":"Mejia-Vilet JM, Zhang XL, Cruz C et al (2020) Urinary soluble CD163: a novel noninvasive biomarker of activity for lupus nephritis. J Am Soc Nephrol 31:1335\u20131347. https:\/\/doi.org\/10.1681\/asn.2019121285","journal-title":"J Am Soc Nephrol"},{"key":"8368_CR48","doi-asserted-by":"publisher","first-page":"6319","DOI":"10.1093\/rheumatology\/keaf446","volume":"64","author":"Y Renaudineau","year":"2025","unstructured":"Renaudineau Y, Treiner E, Colombat M et al (2025) Urinary soluble CD163 is useful to predict lupus nephritis activity and to monitor standard-of-care therapy response. Rheumatol (Oxford) 64:6319\u20136327. https:\/\/doi.org\/10.1093\/rheumatology\/keaf446","journal-title":"Rheumatol (Oxford)"},{"key":"8368_CR49","doi-asserted-by":"publisher","first-page":"100244","DOI":"10.1016\/j.jtauto.2024.100244","volume":"9","author":"Y Renaudineau","year":"2024","unstructured":"Renaudineau Y, Chauveau D, Faguer S et al (2024) Urinary soluble CD163 is useful as \u201cliquid biopsy\u201d marker in lupus nephritis at both diagnosis and follow-up to predict impending flares. J Transl Autoimmun 9:100244. https:\/\/doi.org\/10.1016\/j.jtauto.2024.100244","journal-title":"J Transl Autoimmun"},{"key":"8368_CR50","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1186\/s12967-023-03931-z","volume":"21","author":"DJ Lee","year":"2023","unstructured":"Lee DJ, Tsai PH, Chen CC, Dai YH (2023) Incorporating knowledge of disease-defining hub genes and regulatory network into a machine learning-based model for predicting treatment response in lupus nephritis after the first renal flare. J Transl Med 21:76. https:\/\/doi.org\/10.1186\/s12967-023-03931-z","journal-title":"J Transl Med"},{"key":"8368_CR51","doi-asserted-by":"publisher","first-page":"1288699","DOI":"10.3389\/fimmu.2023.1288699","volume":"14","author":"Z Wang","year":"2023","unstructured":"Wang Z, Hu D, Pei G, Zeng R, Yao Y (2023) Identification of driver genes in lupus nephritis based on comprehensive bioinformatics and machine learning. Front Immunol 14:1288699. https:\/\/doi.org\/10.3389\/fimmu.2023.1288699","journal-title":"Front Immunol"},{"key":"8368_CR52","doi-asserted-by":"publisher","first-page":"829","DOI":"10.1002\/art.42023","volume":"74","author":"A Fava","year":"2022","unstructured":"Fava A, Rao DA, Mohan C et al (2022) Urine proteomics and renal single-cell transcriptomics implicate interleukin-16 in lupus nephritis. Arthritis Rheumatol 74:829\u2013839. https:\/\/doi.org\/10.1002\/art.42023","journal-title":"Arthritis Rheumatol"},{"key":"8368_CR53","doi-asserted-by":"publisher","first-page":"193","DOI":"10.1093\/ndt\/gfae148","volume":"40","author":"X Xia","year":"2024","unstructured":"Xia X, Li S, Jia X et al (2024) Clinicopathological phenotype and outcomes of NCAM-1+ membranous lupus nephritis. Nephrol Dial Transplant 40:193\u2013205. https:\/\/doi.org\/10.1093\/ndt\/gfae148","journal-title":"Nephrol Dial Transplant"},{"key":"8368_CR54","doi-asserted-by":"publisher","first-page":"1912","DOI":"10.1093\/rheumatology\/keae436","volume":"64","author":"F Kharouf","year":"2025","unstructured":"Kharouf F, Li Q, Whittall Garcia LP, Jauhal A, Gladman DD, Touma Z (2025) Short- and long-term outcomes of patients with pure membranous lupus nephritis compared with patients with proliferative disease. Rheumatol (Oxford) 64:1912\u20131922. https:\/\/doi.org\/10.1093\/rheumatology\/keae436","journal-title":"Rheumatol (Oxford)"},{"key":"8368_CR55","doi-asserted-by":"publisher","first-page":"809533","DOI":"10.3389\/fmed.2022.809533","volume":"9","author":"E Kapsia","year":"2022","unstructured":"Kapsia E, Marinaki S, Michelakis I et al (2022) New insights into an overlooked entity: long-term outcomes of membranous lupus nephritis from a single institution inception cohort. Front Med (Lausanne) 9:809533. https:\/\/doi.org\/10.3389\/fmed.2022.809533","journal-title":"Front Med (Lausanne)"},{"key":"8368_CR56","doi-asserted-by":"publisher","first-page":"sfae376","DOI":"10.1093\/ckj\/sfae376","volume":"18","author":"STY Teoh","year":"2025","unstructured":"Teoh STY, Yap DYH, Chan TM (2025) Ten tips in lupus nephritis management. Clin Kidney J 18:sfae376. https:\/\/doi.org\/10.1093\/ckj\/sfae376","journal-title":"Clin Kidney J"},{"key":"8368_CR57","doi-asserted-by":"publisher","first-page":"sfag016","DOI":"10.1093\/ckj\/sfag016","volume":"19","author":"E Morales","year":"2026","unstructured":"Morales E, Galindo M (2026) Clinical trials for lupus nephritis. It is time for change. Clinical Kidney J 19:sfag016. https:\/\/doi.org\/10.1093\/ckj\/sfag016","journal-title":"Clinical Kidney J"},{"key":"8368_CR58","doi-asserted-by":"publisher","first-page":"rkad093","DOI":"10.1093\/rap\/rkad093","volume":"7","author":"MY MdYusof","year":"2023","unstructured":"MdYusof MY, Smith EMD, Ainsworth S et al (2023) Management and treatment of children, young people and adults with systemic lupus erythematosus: British Society for Rheumatology guideline scope. Rheumatol Adv Pract 7:rkad093. https:\/\/doi.org\/10.1093\/rap\/rkad093","journal-title":"Rheumatol Adv Pract"},{"key":"8368_CR59","doi-asserted-by":"publisher","first-page":"461","DOI":"10.1002\/acr.24130","volume":"72","author":"LR Sammaritano","year":"2020","unstructured":"Sammaritano LR, Bermas BL, Chakravarty EE et al (2020) 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Care Res (Hoboken) 72:461\u2013488. https:\/\/doi.org\/10.1002\/acr.24130","journal-title":"Arthritis Care Res (Hoboken)"},{"key":"8368_CR60","doi-asserted-by":"publisher","first-page":"3987","DOI":"10.1007\/s00431-024-05662-9","volume":"183","author":"H Li","year":"2024","unstructured":"Li H, Chen C, Yang H, Tu J (2024) Efficacy and safety of belimumab combined with the standard regimen in treating children with lupus nephritis. Eur J Pediatr 183:3987\u20133995. https:\/\/doi.org\/10.1007\/s00431-024-05662-9","journal-title":"Eur J Pediatr"},{"key":"8368_CR61","doi-asserted-by":"publisher","first-page":"1313","DOI":"10.1007\/s40262-024-01422-y","volume":"63","author":"R Dimelow","year":"2024","unstructured":"Dimelow R, Liefaard L, Green Y, Tomlinson R (2024) Extrapolation of the efficacy and pharmacokinetics of belimumab to support its use in children with lupus nephritis. Clin Pharmacokinet 63:1313\u20131326. https:\/\/doi.org\/10.1007\/s40262-024-01422-y","journal-title":"Clin Pharmacokinet"},{"key":"8368_CR62","doi-asserted-by":"publisher","first-page":"622","DOI":"10.1002\/cpdd.889","volume":"10","author":"R Dimelow","year":"2021","unstructured":"Dimelow R, Ji B, Struemper H (2021) Pharmacokinetics of belimumab in children with systemic lupus erythematosus. Clin Pharmacol Drug Dev 10:622\u2013633. https:\/\/doi.org\/10.1002\/cpdd.889","journal-title":"Clin Pharmacol Drug Dev"},{"key":"8368_CR63","unstructured":"U.S. Food and Drug Administration (2025) BENLYSTA (belimumab) prescribing information.\u00a0[cited 12 July 2026]; Available from:\u00a0https:\/\/www.accessdata.fda.gov\/drugsatfda_docs\/label\/2025\/125370s085lbl.pdf"},{"key":"8368_CR64","unstructured":"ClinicalTrials.gov (2025) A study to evaluate the efficacy, safety, and pharmacokinetics of obinutuzumab in adolescents with active class III or IV lupus nephritis (POSTERITY). [cited 12 July 2026]; Available from: https:\/\/clinicaltrials.gov\/study\/NCT05039619"},{"key":"8368_CR65","doi-asserted-by":"publisher","first-page":"e48","DOI":"10.1093\/rheumatology\/keac551","volume":"62","author":"MD Russell","year":"2023","unstructured":"Russell MD, Dey M, Flint J et al (2023) British society for rheumatology guideline on prescribing drugs in pregnancy and breastfeeding: immunomodulatory anti-rheumatic drugs and corticosteroids. Rheumatol (Oxford) 62:e48\u2013e88. https:\/\/doi.org\/10.1093\/rheumatology\/keac551","journal-title":"Rheumatol (Oxford)"},{"key":"8368_CR66","doi-asserted-by":"publisher","first-page":"347","DOI":"10.1016\/j.semnephrol.2017.05.006","volume":"37","author":"L Lightstone","year":"2017","unstructured":"Lightstone L, Hladunewich MA (2017) Lupus nephritis and pregnancy: concerns and management. Semin Nephrol 37:347\u2013353. https:\/\/doi.org\/10.1016\/j.semnephrol.2017.05.006","journal-title":"Semin Nephrol"},{"key":"8368_CR67","doi-asserted-by":"publisher","first-page":"1390783","DOI":"10.3389\/fneph.2024.1390783","volume":"4","author":"Z GholizadehGhozloujeh","year":"2024","unstructured":"GholizadehGhozloujeh Z, Singh T, Jhaveri KD et al (2024) Lupus nephritis: management challenges during pregnancy. Front Nephrol 4:1390783. https:\/\/doi.org\/10.3389\/fneph.2024.1390783","journal-title":"Front Nephrol"},{"key":"8368_CR68","doi-asserted-by":"publisher","first-page":"199","DOI":"10.2147\/ijwh.S282604","volume":"14","author":"KH Dao","year":"2022","unstructured":"Dao KH, Bermas BL (2022) Systemic lupus erythematosus management in pregnancy. Int J Womens Health 14:199\u2013211. https:\/\/doi.org\/10.2147\/ijwh.S282604","journal-title":"Int J Womens Health"},{"key":"8368_CR69","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1186\/s12882-020-01888-5","volume":"21","author":"RD Wright","year":"2020","unstructured":"Wright RD, Bannerman F, Beresford MW, Oni L (2020) A systematic review of the role of eculizumab in systemic lupus erythematosus-associated thrombotic microangiopathy. BMC Nephrol 21:245. https:\/\/doi.org\/10.1186\/s12882-020-01888-5","journal-title":"BMC Nephrol"},{"key":"8368_CR70","doi-asserted-by":"publisher","first-page":"e001375","DOI":"10.1136\/lupus-2024-001375","volume":"12","author":"P Vidal-Montal","year":"2025","unstructured":"Vidal-Montal P, Narv\u00e1ez J, Fulladosa X et al (2025) Outcomes following immunosuppressive therapy withdrawal after complete renal response in proliferative lupus nephritis. Lupus Sci Med 12:e001375. https:\/\/doi.org\/10.1136\/lupus-2024-001375","journal-title":"Lupus Sci Med"},{"key":"8368_CR71","doi-asserted-by":"publisher","first-page":"1894","DOI":"10.1093\/rheumatology\/keae381","volume":"64","author":"A Panagiotopoulos","year":"2025","unstructured":"Panagiotopoulos A, Kapsia E, El Michelakis I et al (2025) Immunosuppressives discontinuation after renal response in lupus nephritis: predictors of flares, time to withdrawal and long-term outcomes. Rheumatol (Oxford) 64:1894\u20131903. https:\/\/doi.org\/10.1093\/rheumatology\/keae381","journal-title":"Rheumatol (Oxford)"},{"key":"8368_CR72","doi-asserted-by":"publisher","first-page":"e001825","DOI":"10.1136\/lupus-2025-001825","volume":"13","author":"P Vidal-Montal","year":"2026","unstructured":"Vidal-Montal P, Fabregat A, Altab\u00e1s-Gonz\u00e1lez I et al (2026) Real-world experience with belimumab-based triple therapy in proliferative lupus nephritis: data from the BEL-SPAIN Registry. Lupus Sci Med 13:e001825. https:\/\/doi.org\/10.1136\/lupus-2025-001825","journal-title":"Lupus Sci Med"},{"key":"8368_CR73","doi-asserted-by":"publisher","first-page":"102729","DOI":"10.1016\/j.jaut.2021.102729","volume":"124","author":"M Gatto","year":"2021","unstructured":"Gatto M, Saccon F, Andreoli L et al (2021) Durable renal response and safety with add-on belimumab in patients with lupus nephritis in real-life setting. (BeRLiSS-LN) Results from a large, nationwide, multicentric cohort. J Autoimmun 124:102729. https:\/\/doi.org\/10.1016\/j.jaut.2021.102729","journal-title":"J Autoimmun"},{"key":"8368_CR74","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2025.1702550","volume":"16","author":"C Wu","year":"2025","unstructured":"Wu C, Wang Y, Chen S et al (2025) Obinutuzumab in systemic lupus erythematosus: a real-world experience. Front Immunol 16:1702550. https:\/\/doi.org\/10.3389\/fimmu.2025.1702550","journal-title":"Front Immunol"},{"key":"8368_CR75","doi-asserted-by":"publisher","first-page":"385","DOI":"10.2215\/cjn.13030921","volume":"17","author":"O Mandrik","year":"2022","unstructured":"Mandrik O, Fotheringham J, Ren S et al (2022) The cost-effectiveness of belimumab and voclosporin for patients with lupus nephritis in the United States. Clin J Am Soc Nephrol 17:385\u2013394. https:\/\/doi.org\/10.2215\/cjn.13030921","journal-title":"Clin J Am Soc Nephrol"},{"key":"8368_CR76","doi-asserted-by":"publisher","first-page":"1495","DOI":"10.18553\/jmcp.2021.27.10.1495","volume":"27","author":"JA Tice","year":"2021","unstructured":"Tice JA, Mandrik O, Thokala P, Fotheringham J, Pearson SD (2021) The effectiveness and value of belimumab and voclosporin for lupus nephritis. J Manag Care Spec Pharm 27:1495\u20131499. https:\/\/doi.org\/10.18553\/jmcp.2021.27.10.1495","journal-title":"J Manag Care Spec Pharm"},{"key":"8368_CR77","doi-asserted-by":"publisher","first-page":"773","DOI":"10.18553\/jmcp.2024.23324","volume":"30","author":"L Kennedy","year":"2024","unstructured":"Kennedy L, Lee E, Flauto R, Atencio V, Birardi V (2024) Evaluating the cost-effectiveness of voclosporin for the treatment of lupus nephritis in the United States. J Manag Care Spec Pharm 30:773\u2013781. https:\/\/doi.org\/10.18553\/jmcp.2024.23324","journal-title":"J Manag Care Spec Pharm"}],"container-title":["Clinical Rheumatology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08368-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10067-026-08368-5","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10067-026-08368-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,16]],"date-time":"2026-09-16T08:05:00Z","timestamp":1789545900000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10067-026-08368-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,8,24]]},"references-count":77,"journal-issue":{"issue":"10","published-print":{"date-parts":[[2026,10]]}},"alternative-id":["8368"],"URL":"https:\/\/doi.org\/10.1007\/s10067-026-08368-5","relation":{},"ISSN":["0770-3198","1434-9949"],"issn-type":[{"value":"0770-3198","type":"print"},{"value":"1434-9949","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,8,24]]},"assertion":[{"value":"4 June 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"6 August 2026","order":2,"name":"revised","label":"Revised","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"15 August 2026","order":3,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"24 August 2026","order":4,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"Not applicable.","order":1,"name":"Ethics","label":"Ethics approval","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"Not applicable.","order":2,"name":"Ethics","label":"Consent to participate","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}},{"value":"None.","order":3,"name":"Ethics","label":"Disclosures","group":{"name":"EthicsHeading","label":"Compliance with ethical standards"}}]}}